GBT and Sickle Cell Disease Association of America Kick Off “Lift Every Voice to Shine the Light on Sickle Cell” Spoken Word Contest in Honor of World Sickle Cell Day 2021
04 mai 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and HANOVER, Md., May 04, 2021 (GLOBE NEWSWIRE) -- In recognition of World Sickle Cell Day, which falls on June 19, 2021, Global Blood Therapeutics, Inc. (GBT) (NASDAQ:...
GBT to Announce First Quarter 2021 Financial Results on Wednesday, May 5, 2021
28 avr. 2021 07h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2021 financial results on...
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
08 avr. 2021 03h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced The Lancet Haematology has published the complete analysis of...
GBT Announces New Employment Inducement Grants
05 avr. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on April 1, 2021, the compensation committee of GBT’s board...
GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors
18 mars 2021 07h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a...
GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
16 mars 2021 07h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced it has entered into an agreement with Sanofi S.A. to exclusively...
GBT Announces New Employment Inducement Grants
08 mars 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2021, the compensation committee of GBT’s board...
GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community
02 mars 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it is accepting proposals for the third annual Access to...
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
02 mars 2021 07h30 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) will participate at the H.C. Wainwright Global Life Sciences Conference on...
GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
24 févr. 2021 16h05 HE
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $41.3 million in the fourth quarter and $123.8 million for full year 2020 Further established leadership in sickle cell disease (SCD) with data...